Icon (NASDAQ:ICLR) Issues FY 2026 Earnings Guidance

Icon (NASDAQ:ICLR) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 10.000-11.000 for the period, compared to the consensus EPS estimate of 11.330. The company issued revenue guidance of $7.9 billion-$8.2 billion, compared to the consensus revenue estimate of $7.9 billion.

Icon Price Performance

Shares of ICLR stock opened at $118.45 on Thursday. The stock has a 50-day moving average price of $111.55 and a 200 day moving average price of $141.66. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. The firm has a market cap of $9.57 billion, a price-to-earnings ratio of 16.03, a PEG ratio of 2.97 and a beta of 1.23. Icon has a 12 month low of $66.57 and a 12 month high of $211.00.

Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, May 27th. The medical research company reported $2.52 EPS for the quarter, missing analysts’ consensus estimates of $3.14 by ($0.62). The firm had revenue of $2.11 billion during the quarter, compared to analyst estimates of $1.98 billion. Icon had a return on equity of 10.58% and a net margin of 7.40%.Icon’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.43 earnings per share. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. Research analysts expect that Icon will post 11.53 EPS for the current year.

Wall Street Analysts Forecast Growth

ICLR has been the subject of a number of research reports. Rothschild & Co Redburn set a $100.00 price objective on Icon and gave the stock a “neutral” rating in a research report on Tuesday, February 17th. Robert W. Baird set a $119.00 price objective on Icon in a research report on Friday, February 13th. Leerink Partners set a $125.00 price objective on Icon in a research report on Monday, May 4th. Bank of America restated an “underperform” rating and set a $105.00 target price on shares of Icon in a research report on Wednesday. Finally, TD Cowen upgraded Icon from a “hold” rating to a “buy” rating and decreased their target price for the stock from $183.00 to $120.00 in a research report on Wednesday, February 18th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $147.67.

Hedge Funds Weigh In On Icon

Several institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP grew its position in shares of Icon by 26.6% during the 3rd quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock worth $811,499,000 after buying an additional 975,268 shares during the period. Orbis Allan Gray Ltd lifted its holdings in shares of Icon by 1.8% during the 4th quarter. Orbis Allan Gray Ltd now owns 4,214,661 shares of the medical research company’s stock valued at $767,996,000 after purchasing an additional 75,843 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Icon by 9.6% during the 4th quarter. Invesco Ltd. now owns 3,756,896 shares of the medical research company’s stock valued at $684,582,000 after purchasing an additional 329,266 shares in the last quarter. Harris Associates L P lifted its holdings in shares of Icon by 7.2% during the 4th quarter. Harris Associates L P now owns 2,510,166 shares of the medical research company’s stock valued at $457,402,000 after purchasing an additional 167,607 shares in the last quarter. Finally, Ruane Cunniff & Goldfarb L.P. lifted its holdings in shares of Icon by 36.2% during the 2nd quarter. Ruane Cunniff & Goldfarb L.P. now owns 1,708,183 shares of the medical research company’s stock valued at $248,455,000 after purchasing an additional 453,833 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.